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OBJECTIVES: To examine whether the Markov chain/
decision tree approach is better than the cost function
approach in modeling the pharmaceutical costs for 
Attention Deﬁcit/Hyperactivity Disorder (ADHD).
METHODS: Using one half sample of a nationally rep-
resentative large claim data set (Pharmetrics claim data-
base), we applied both the Markov Chain/decision tree
approach and cost function approach to model the phar-
maceutical costs for attention deﬁcit/hyperactivity disor-
der. Then, we examined both the validity and reliability
of these two models. In terms of validity, we examined
whether and how the model assumptions are satisﬁed
under each approach. In terms of reliability, we used
another half sample of the claim data set to test the two
models. RESULTS: More assumptions were violated in
the Markov chain/decision tree model than in cost func-
tion. One example of these violated assumptions is that
Markov chain/decision tree approach assumes the inde-
pendence of transition probabilities. Furthermore,
because that claim data do not provide many parameters
required in the Markov chain/decision tree model, the
Markov chain/decision tree approach has used many arbi-
trary estimates, which made model very unreliable. The
examples of these parameters are the rate of adequate
response of each medication, the rate of titration up or
down, the rate of switching between medications, the tol-
erable rate of each medication, and drop out rate. CON-
CLUSIONS: The Markov chain/decision tree approach is
not necessary better than cost function approach in mod-
eling pharmaceutical costs. When modelers do not have
solid estimates of those transition probabilities and when
the assumptions underlying this approach are violated,
cost function approach may be better than the Markov
chain/decision tree approach. The limitation of cost func-
tion approach is that it does not give clinical process
information as rich as the Markov chain/decision tree
approach.
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PROBABILISTIC SENSITIVITY ANALYSES:
COMMONLY RECOMMENDED, UNCOMMONLY
PERFORMED
Rocchi A, Chin W
Axia Research, Hamilton, ON, Canada
OBJECTIVE: Guidelines for the economic evaluation of
pharmaceuticals in Canada (CCOHTA, 1997) and the US
(Gold et al., 1996) encourage the use of probabilistic 
sensitivity analyses (SA). Increasingly, the literature also
reports and supports the use of probabilistic SA over the
traditional univariate and multivariate SA. Poster pre-
sentations from the ISPOR May 2002 conference were
reviewed to identify if users were producing the encour-
aged probabilistic SA. It was recognized that abstracts do
not permit comprehensive methodology description, but
given the fundamental importance of SA, it was expected
that minimum information expectations should be met.
METHODS: Abstracts of the ISPOR May 2002 poster
presentations were published in Value in Health
May/June 2002. All abstracts classiﬁed under “Economic
Outcomes” were reviewed to identify original economic
evaluations. Each identiﬁed evaluation was examined for
its reporting and use of SA; these were classiﬁed by SA
methodology (unknown, univariate, multivariate, proba-
bilistic). RESULTS: Of 154 abstracts with economic out-
comes, 50 were original economic evaluations. Of these,
16 (32%) did not mention SA at all. The remaining 34
abstracts (68%) mentioned the use of SA. Of these, 15
(44%) explicitly stated the SA methodology; methodol-
ogy was implicit by results reporting for a further 10
abstracts (29%); methodology was indeterminable for the
ﬁnal 9 abstracts (26%). Of the 25 abstracts for which SA
methodology was determinable, 16 (64%) used only uni-
variate analysis, 8 (28%) used multivariate analysis, and
2 (8%) used probabilistic analysis. CONCLUSIONS:
Despite the encouragement of the literature and guide-
lines, probabilistic SA remain uncommon in economic
evaluations. Moreover, the adequate reporting of SA was
uncommon in the May 2002 ISPOR poster abstracts.
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OBJECTIVES: With increasing emphasis on using pub-
lished evidence to quantify the value of drug treatment,
we assessed the value of adding search terms identiﬁed
from key articles to initial search strategies to locate
studies in large subject areas. METHODS: Systematic
review in ﬁve chronic disease settings (asthma, depres-
sion, diabetes, GI disorders, and migraine), including
development of pre-deﬁned criteria for study inclusion.
Outcomes of interest were those relevant to the value of
pharmaceutical treatment (economic, societal, and/or
patient beneﬁt). We constructed a MEDLINE search (via
PubMed) with terms indicating drug treatment (“drug
therapy” subheading) and outcomes (“Economics, phar-
maceutical”, “Costs and Cost Analysis,” and “Quality of
life” MeSH terms). We then reviewed indexing terms
present in key articles found independently of the initial
search, using an iterative process. Terms which led to
identiﬁcation of new, relevant citations without excessive
